Play safer with PolarCap®

Get in touch

Clinical cohort study in treatment of concussion

The clinical pilot study with PolarCap® System as treatment method for concussion in ice hockey, has now been analyzed in collaboration with the Department of Mathematics at Umeå University and the company's scientific advisors, Professor Emeritus Yelverton Tegner and Professor Niklas Marklund. The study aimed to examine symptom development and time to return to play, following a concussion.

A total of 12 teams from Swedish Hockey League (SHL) and HockeyAllsvenskan have participated in the study; The intervention group has used PolarCap® System and the control group has consisted of players who have not received the treatment. PolarCap® System was placed in the medical rooms of the participating teams and enabled swift treatment following a diagnosed or suspected concussion. The participants were cooled during 30-60 minutes.

A total of 80 cases were reported in the study. The median time for return to play for the intervention group, treated with PolarCap® System, was 7 days and for

those not treated 12 days. The results are statistically significant (p < 0.001).

In addition, more players in the control group (12 of 51; 24%) were absent from games longer than 3 weeks, compared to the intervention group (2 of 29; 7%). These results are also statistically significant (p = 0.028).

None of the participants who were treated with PolarCap® System indicated that they would refuse treatment if they experienced a new concussion.

These findings are important considering that curtailed absence after brain injury due to treatment with PolarCap® System generates financial benefits for athletes, sports teams, and insurance companies. Above all, the social and health benefits consist of the potential limited neurological damage as a result of treatment with PolarCap® System.

The study has generated positive feedback from medical teams as well as from athletes. Overall, the results show that early cooling as an acute treatment method for concussions in this study has had positive effects.

Clinical study in treatment of sub-concussive repetitive head impact

PolarCool has recently completed a study targeting the potential neurodegenerative pathology that repetitive head collisions generate, and the results are currently being analyzed.

The study evaluates the effect of cooling on sub-concussive brain injuries by analyzing inflammatory biomarkers from blood samples taken before and after cooling. Baseline blood samples were collected during the-preason, prior to full contact activities initiated. PolarCool intends to demonstrate that cooling with the PolarCap® System relieves symptoms of brain injury that may arise as a result of repetitive head impact.

This is demonstrated by comparing the development of biomarkers from blood samples taken before and after cooling, following practice or games.

The protein secreted in the brain and the blood subsequent of head trauma can be identified by inflammatory biomarkers such as Tau, Nfl, and GFAP.  The biomarkers could indicate axonal damage in the brain’s white matter areas.

Multiple PolarCap® System devcies were stationed Limhamn Griffin’s facilities at Hästhagens Idrottsplats in Malmö. During the course of study, brain cooling was applied for 60 minutes after practice or game, after which blood samples were taken from both intervention and control groups.

The study is conducted in collaboration with Skåne’s University Hospital (Region Skåne), Biomedicinskt Centrum in Lund (part of Lund University),  and Limhamn Griffins Sportklubb. The results of the study are expected to be communicated in the third quarter of 2019.